Cymbalta (duloxetine) is a prescription drug that treats major depressive disorder, anxiety disorder, and other conditions. Its cost may depend on factors such as dosage, whether you have health ...

Gradually taper off Cymbalta with help from your healthcare provider to avoid severe withdrawal symptoms. Stopping Cymbalta suddenly can cause symptoms like dizziness, nausea, and trouble sleeping.

A popular antidepressant, often known by the brand name Cymbalta, was recalled last week due to the presence of a potentially cancer-causing chemical. More than 233,000 bottles of duloxetine capsules ...

It could be another Prozac moment. Eli Lilly and Co. is pitching its next star antidepressant drug, Cymbalta, for approval to treat the poorly understood pain of fibromyalgia. Regulators OK’d a drug ...

INDIANAPOLIS, June 3 /PRNewswire-FirstCall/ -- As projected, Eli Lilly and Company (NYSE: LLY) has resubmitted its supplemental New Drug Application (sNDA) for ...

The U.S. Food and Drug Administration has recalled thousands of bottles of the antidepressant Duloxetine for potentially cancer-causing chemicals above the acceptable limit set by the FDA, per the ...

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary recall ...

Do you need help with the cost of Cymbalta? Cymbalta was developed by Eli Lilly and Company for use in the treatment of depression, generalized anxiety disorder, major depressive disorder, ...

The U.S. Food and Drug Administration has recalled thousands of bottles of the antidepressant duloxetine over the presence of a toxic chemical. According to an Oct. 10 notice from the agency, the ...

In addition to depression, doctors can prescribe Cymbalta to treat anxiety that lasts for at least six months, pain from diabetic nerve damage, fibromyalgia, and long-term muscle or bone pain. It ...

INDIANAPOLIS, June 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- As projected, Eli Lilly and Company (NYSE: LLY) has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta(R ...